Sustained LDL-Cholesterol Reduction with Incl...

Sustained LDL-Cholesterol Reduction with Inclisiran: A Review Study

Author Name : Agrima Sidharthan T, Aji Varghese

ABSTRACT

Globally, atherosclerotic cardiovascular diseases (ASCVD), such as myocardial infarction, stroke, and peripheral artery disease, continue to be major causes of early death, disability, and healthcare spending. Due to its well-established advantages in terms of reduced mortality, the lowering of LDL-C is the main aim for the lowering of cvd risk and the best indicator of clinical success under lipid-lowering therapy. LDL-C receptors play a critical role in the emergence of ASCVD. PCSK9 controls how long LDL receptors live. When PCSK9 is inhibited, LDL-C clearance from the bloodstream improves and the plasma concentration of LDL-C is substantially reduced. When cell-surface receptor density is decreased, LDL-C levels in the blood are increased. Proprotein convertase subtilisin-kexin type 9 (PCSK9), a serine protease that regulates the levels of plasma low-density lipoprotein cholesterol (LDL-C), is the target of the long-acting, synthetic small interfering RNA (siRNA) known as inclisiran. Inclisiran lowers PCSK9 concentrations and plasma level of LDL cholesterol by binding to the PCSK9 messenger RNA and inhibiting PCSK9 protein synthesis. Additional benefit of lowering plasma LDL-C levels is that it lowers the risk of heart disease (CVD) and improves cardiovascular outcomes. In this review, we summarize the general information regarding the role of LDL-C in atherosclerotic cardiovascular disease, role of PCSK9 in cholesterol metabolism and about inclisiran’s potential future role in cardiovascular disease.

Keywords: Cardiovascular Diseases, Inclisiran, LDL-Cholesterol Reduction, Pcsk9.